Reduced-intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed non-Hodgkin and Hodgkin's lymphomas

被引：0
作者：
Corradini, P
Dodero, A
Bregni, M
Olivieri, A
Valagussa, P
Farina, L
Milani, R
Scime, R
Rambaldi, A
Bonifazi, F
Patriarca, F
Locasciulli, A
Bacigalupo, A
Gianni, A
Tarella, C
机构：
[1] Ist Nazl Tumori, I-20133 Milan, Italy
[2] Ist San Raffaele, Milan, Italy
[3] Univ Ancona, Ancona, Italy
[4] Opsed Cervello, Palermo, Italy
[5] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[6] Osped St Orsola, Bologna, Italy
[7] Univ Udine, I-33100 Udine, Italy
[8] Osped San Camillo, Rome, Italy
[9] Osped San Martino Genova, Genoa, Italy
[10] Univ Turin, Turin, Italy
来源：
BONE MARROW TRANSPLANTATION | 2006年 / 37卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
[41]   Positron emission tomography scan performed before reduced-intensity conditioning allogeneic stem cell transplantation has a prognostic value in patients with relapsed and chemosensitive Hodgkin's lymphoma or aggressive non-Hodgkin lymphoma [J].
Dodero, A. ;
Crocchiolo, R. ;
Patriarca, F. ;
Castagna, L. ;
Ciceri, F. ;
Frungillo, N. ;
Fanin, R. ;
Bramanti, S. ;
Miceli, R. ;
Assanelli, A. ;
Milani, R. ;
Crippa, F. ;
Corradini, P. .
BONE MARROW TRANSPLANTATION, 2008, 41 :S42-S43
[42]   Reduced-intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma: no benefit of graft-versus-lymphoma effect [J].
Lerner, D. ;
Arcuri, L. ;
Maiolino, A. ;
Sousa, A. ;
Tavares, R. ;
Colares, M. ;
Matos, M. ;
Azevedo, A. ;
Bouzas, L. F. .
BONE MARROW TRANSPLANTATION, 2011, 46 :S250-S251
[43]   Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma [J].
Vijaya Raj Bhatt .
Current Hematologic Malignancy Reports, 2016, 11 :196-207
[44]   Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma [J].
Bhatt, Vijaya Raj .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (03) :196-207
[45]   Reduced-intensity rituximab-BEAM-CAMPATH allogeneic transplantation for indolent non-Hodgkin's lymphoma. [J].
Ho, AYL ;
Devereux, S ;
Mufti, GL ;
Pagliuca, A .
BLOOD, 2001, 98 (11) :188A-188A
[46]   GVT effect of reduced-intensity allogeneic transplantation for Hodgkin's lymphoma [J].
Marie Lofthouse .
Nature Clinical Practice Oncology, 2005, 2 (9) :432-432
[47]   Allogeneic haemopoietic stem cell transplantation for non-Hodgkin's lymphoma [J].
Toze, CL ;
Barnett, MJ .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (03) :481-504
[48]   Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem cell transplantation in patients with chemorefractory non-Hodgkin lymphoma [J].
Shimoni, A ;
Zwass, T ;
Oksman, Y ;
Hardan, I ;
Shem-Tov, N ;
Yerushalmi, R ;
Avigdor, A ;
Ben-Bassat, I ;
Nagler, A .
BONE MARROW TRANSPLANTATION, 2006, 37 :S234-S234
[49]   Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation [J].
K J Thomson ;
K S Peggs ;
P Smith ;
J Cavet ;
A Hunter ;
A Parker ;
R Pettengell ;
D Milligan ;
E C Morris ;
A H Goldstone ;
D C Linch ;
S Mackinnon .
Bone Marrow Transplantation, 2008, 41 :765-770
[50]   Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases [J].
Picleanu, Ana M. ;
Novelli, Silvana ;
Monter, Anna ;
Garcia-Cadenas, Irene ;
Caballero, Ana C. ;
Martino, Rodrigo ;
Esquirol, Albert ;
Briones, Javier ;
Sierra, Jorge .
ANNALS OF HEMATOLOGY, 2017, 96 (05) :787-796
12345